Subclinical Eye Movement Disorders in Patients with Multiple Sclerosis
Neurol 27:614, Solingen,L.D.,et al, 1977
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Incidence of Radiologically Isolated Syndrome: A Population-Based Study
AJNR 37:1017-1022, Forslin, Y.,et al, 2016
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Incidental MRI Anomalies Suggestive of Multiple Sclerosis: The Radiologically Isolated Syndrome
Neurol 72:800-805,780, Okuda,D.T.,et al, 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
General Neurologist and Subspecialist Care for Multiple Sclerosis, Patients' Perceptions
Neurol 53:1190-1197, Vickrey,B.G.,et al, 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Measuring Patient-Centered Outcomes in Neurologic Disease, Extending the Q-TWIST Method
Arch Neurol 52:754-762, Schwartz,C.,et al, 1995
The Value of Diagnostic Information to Patients with Suspected Multiple Sclerosis
Arch Neurol 51:67-72, Mushlin,A.I.,et al, 1994
Effect of Diagnostic Testing for Multiple Sclerosis on Patient Health Perceptions
Arch Neurol 51:46-51, O'Connor,P.,et al, 1994
Clinicopath Conf
Acute Multiple Sclerosis, Case Record 42-1990, NEJM 323:1123-1135990., , 1990
Suspicion of Multiple Sclerosis, To Tell or Not To Tell
Arch Neurol 45:441-442, Sencer,W., 1988
Explanation & Management of Neurological Disability
BMJ 294:1203-1205, Critchley,E.M.R.&Mitchell,J.D., 1987
To Tell or Not To Tell the Diagnosis of Multiple Sclerosis
Lancet 2:26, 27-281985., Elian,M.,et al, 1985
Evoked Potentials in Neurological Diagnosis
BMJ 285:1678-1679, Mastaglia,F.L.,et al, 1982
Neuro CPC of MGH
Multiple Sclerosis, Cerebral Infarcts, & Colitis, NEJM 268:607-615., , 1963